Information Provided By:
Fly News Breaks for February 25, 2016
BLUE
Feb 25, 2016 | 06:10 EDT
Piper Jaffray analyst Joshua Schimmer lowered his price target for bluebird bio to $117 citing higher spend estimates following the company's Q4 results. The new price target still reflects greater than 100% upside from current levels, Schimmer tells investors in a research note. "By the end of the year we believe LentiGlobin will be back on track with a profile poised to deliver cures for most patients with hemoglobinopathies," the analyst writes. He keeps an Overweight rating on the shares.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.